文献速递慢病管理

激励与公平:一项改善社会经济弱势糖尿病患者血糖控制的随机对照试验

Incentives and Equity: A Randomized Controlled Trial to Improve Glycemic Control in Socioeconomically Disadvantaged Patients With Diabetes.
PubMed 文献 · Ann Fam Med · 2026-01-26

该随机对照试验纳入186例血糖控制不佳的2型糖尿病患者,来自低社会经济地位社区,干预组根据血糖控制改善情况给予最高600新谢克尔(约156美元)的药费折扣券,对照组常规自付药费。结论认为经济激励有助于改善弱势人群的糖尿病控制。

要点

  • 干预组6个月HbA1c平均降1.4%,对照组降0.7%。
  • 多因素校正后组间HbA1c降幅差异0.7%(95%CI 0.3%-1.2%)。
  • 经济激励或可整合为弱势地区慢病患者的可选项目。

核心结论

  • 有条件降低药费自付的经济激励可改善低社会经济地位2型糖尿病患者的血糖控制。

研究设计与样本

  • 随机对照试验,从低社会经济地位社区招募186例血糖控制不佳的2型糖尿病患者,随机分为干预组和对照组。

主要发现

  • 基线平均HbA1c为9.1%。
  • 6个月符合方案分析中,干预组HbA1c平均降低1.4%(95%CI 1.1%-1.7%),对照组降低0.7%(95%CI 0.3%-1.0%),P<.001。
  • 多因素线性回归校正年龄、性别、基线HbA1c、BMI、社会部门、收入、教育及糖尿病病程后,组间HbA1c降幅差异为0.7%(95%CI 0.3%-1.2%,P=.001)。

关键数值与推荐

  • 干预组可获得药费折扣(最高600新以色列谢克尔或156美元,通过药店可兑换的代金券发放),以血糖控制改善为条件。
  • 对照组按常规支付药费。

临床怎么用

  • 在低社会经济地位地区,可考虑将基于血糖控制改善的药费折扣作为慢病管理可选激励项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite availability of effective diabetes medications, 27% of Israeli patients did not reach glycemic control goals in 2019. Financial hardship markedly impacts diabetes management. The American Diabetes Association recommends financial incentive initiatives as part of quality improvement programs. We investigated the impact of a conditional reduction in medication out-of-pocket costs vs standard payment on glycemic control. METHODS: A total of 186 patients with uncontrolled type 2 diabetes were recruited from neighborhoods having low socioeconomic status and randomly assigned to an intervention group or a control group. Patients in the intervention group were offered a discount on drug expenses (up to 600 new Israeli shekels or US $156, distributed through vouchers redeemable at pharmacies) that was conditional on improved glycemic control. Patients in the control group paid for their medications as usual. RESULTS: At baseline, study participants had a mean glycated hemoglobin (HbA1c) level of 9.1%. The mean reduction in HbA1c level at 6 months in per protocol analysis was 1.4% (95% CI, 1.1%-1.7%) in the intervention group and 0.7% (95% CI, 0.3%-1.0%) in the control group (P <.001). Multivariate linear regression analysis also demonstrated a significant difference in HbA1c reduction between groups (difference = 0.7%; 95% CI, 0.3%-1.2%;P = .001) after controlling for age, sex, baseline HbA1c level, body mass index, societal sector, income, education, and diabetes duration. CONCLUSIONS: Financial incentives have the potential to enhance diabetes control in populations having low socioeconomic status and could be integrated into health plans as an optional program for patients with chronic disease in disadvantaged areas.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Prigozin A, Cohen MJ, Mosenzon O, et al. Incentives and Equity: A Randomized Controlled Trial to Improve Glycemic Control in Socioeconomically Disadvantaged Patients With Diabetes. Ann Fam Med. 2026. PMID: 41587834. doi:10.1370/afm.240556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。